A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study

Summary Background The effectiveness of reintroducing oxaliplatin for metastatic colorectal cancer (mCRC) refractory to both oxaliplatin and irinotecan was previously reported in a phase II study (RE-OPEN). We conducted a phase I study to determine the maximum tolerated dose of oxaliplatin plus trif...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Investigational new drugs 2020-02, Vol.38 (1), p.111-119
Hauptverfasser: Suenaga, Mitsukuni, Wakatsuki, Takeru, Mashima, Tetsuo, Ogura, Mariko, Ichimura, Takashi, Shinozaki, Eiji, Nakayama, Izuma, Osumi, Hiroki, Ota, Yumiko, Takahari, Daisuke, Chin, Keisho, Seimiya, Hiroyuki, Yamaguchi, Kensei
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!